Bullish indicating open at $55-$60, IPO prices at $37
ZURICH - NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss biopharmaceutical company with a market capitalization of $2.81 million, announced its plans to present preclinical data on Mazindol ER, a central nervous system (CNS) disorder treatment candidate, at the upcoming 2025 Annual Meeting of the American Society of Clinical Psychopharmacology (ASCP). According to InvestingPro data, the company maintains a solid financial position with more cash than debt and a healthy current ratio of 2.69. The meeting is scheduled to take place in Scottsdale, Arizona, from May 27 to May 30, 2025.
The data emanates from a study titled ’Evaluating the Effects of Mazindol on Fentanyl Reward and Dependence in C57BL/6J Mice and Sprague-Dawley Rats (Study KO-943),’ which will be showcased during a poster session on May 29. While the company’s research progresses, InvestingPro analysis reveals the company is quickly burning through cash, highlighting the importance of successful clinical developments. Get access to 8 more exclusive ProTips and detailed financial metrics with InvestingPro. Conducted by Key-Obs SAS in collaboration with NLS and European academic institutions, the study presents findings that Mazindol significantly reduced the rewarding effects of fentanyl and the severity of its withdrawal symptoms in validated rodent models.
Dr. Jean-Charles Bizot, Director of Research at Key-Obs SAS and the lead investigator of the study, commented on the results, stating, "Mazindol produced robust effects on both reward and withdrawal symptoms, demonstrating its potential as a non-opioid therapeutic candidate option for fentanyl dependence." He emphasized the importance of further clinical trials to validate these findings in humans.
The study’s results are particularly relevant as Mazindol’s multi-receptor activity, targeting partial mu-opioid receptor agonism, strong 5-HT1A receptor agonist activity, and orexin-2 receptor modulation, could represent a novel mechanism of action for addressing opioid addiction. Dr. Eric Konofal, MD, PhD, Chief Scientific Officer of NLS Pharmaceutics, noted that these findings support the potential of Mazindol as a non-opioid therapeutic and the need for clinical trials, including the planned NLS-6002 study.
NLS Pharmaceutics focuses on developing therapies for rare and complex CNS disorders, including ADHD, narcolepsy, hypersomnia, and substance use disorders, emphasizing repurposed and reformulated compounds.
The ASCP Annual Meeting is a leading event for the neuropsychopharmacology and psychiatry fields, where clinicians and researchers converge to discuss CNS therapeutics advances.
The information in this article is based on a press release statement from NLS Pharmaceutics Ltd. It should be noted that forward-looking statements made by the company are subject to various risks and uncertainties that could cause actual results to differ materially from those projected. This is reflected in the company’s stock performance, which has declined by 71.73% over the past year, though it has shown strong returns over the last month according to InvestingPro data.
In other recent news, NLS Pharmaceutics has secured $2 million in equity financing to support its anticipated merger with Kadimastem Ltd., a company focused on cell therapy for neurodegenerative diseases and diabetes. This merger aims to advance treatments in regenerative medicine and central nervous system disorders, subject to regulatory and shareholder approvals. Additionally, NLS Pharmaceutics has established a $25 million committed equity facility agreement to facilitate clinical trials for Kadimastem’s AstroRx® for ALS and IseltRx for type 1 diabetes. In another development, NLS Pharmaceutics, in collaboration with Aexon Labs Inc., reported promising preclinical results for AEX-2, a potential treatment for narcolepsy. The drug, a dual orexin receptor agonist, demonstrated enhanced wakefulness and reduced cataplexy in animal models. The findings suggest AEX-2 and another compound, AEX-41, may have broader applications in neurodegenerative and metabolic disorders. NLS Pharmaceutics plans to advance these compounds into IND-enabling studies, aiming for human trials by 2026. CEO Alex Zwyer has highlighted the transformative potential of these developments for the company’s treatment landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.